Assetmark, Inc Ultragenyx Pharmaceutical Inc. Transaction History

Assetmark, Inc

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 01, 2022	SELL	$39.96 - $66.14 $180,699 - $299,085	-4,522 Reduced 99.6%	18 $1,000
Q2 2022 Aug 03, 2022	BUY	$45.8 - $85.4 $4,671 - $8,710	102 Added 2.3%	4,540 $271,000
Q1 2022 May 13, 2022	BUY	$62.2 - $84.4 $146,418 - $198,677	2,354 Added 112.96%	4,438 $322,000
Q4 2021 Feb 14, 2022	BUY	$73.71 - $87.86 $147,788 - $176,159	2,005 Added 2537.97%	2,084 $175,000
Q3 2021 Nov 12, 2021	BUY	$77.92 - $102.4 $6,155 - $8,089	79 New	79 $7,000
Q1 2020 May 12, 2020	SELL	$33.8 - $62.9 $1,047 - $1,949	-31 Closed	0 $0
Q3 2019 Nov 13, 2019	BUY	$42.5 - $63.11 $765 - $1,135	18 Added 138.46%	31 $1,000
Q1 2019 May 14, 2019	SELL	$39.87 - $69.36 $39 - $69	-1 Reduced 7.14%	13 $1,000
Q4 2018 Feb 13, 2019	BUY	$38.89 - $77.3 $544 - $1,082	14 New	14 $1,000
Q1 2018 May 16, 2018	SELL	$44.33 - $58.52 $531 - $702	-12 Closed	0 $0
Q4 2017 Feb 13, 2018	BUY	$43.54 - $57.32 $304 - $401	7 Added 140.0%	12 $1,000
Q4 2015 Sep 15, 2017	BUY	N/A	5	5 $1,000

325

85.5M

520K

406K

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.14B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

Get notified when there are updates to the investment portfolio of Assetmark, Inc, based on Form 13F filings with the SEC.

Stay updated on Assetmark, Inc with notifications on news.